Annovis Bio (ANVS) Stock Surge Following Promising Clinical Trial Results

Following a notable advancement in clinical trials, shares of Annovis Bio, Inc. (NYSE: ANVS) have experienced a significant uptick. As of the latest market check today, ANVS stock has surged by 30.32%, reaching a price of $10.53.

Promising Phase III PD Study Results

Buntanetap is safe and effective, according to new findings from Annovis Bio (ANVS) Phase III Parkinson’s Disease (PD) trial. Patients with early-stage Parkinson’s disease have demonstrated improvements in their motor and non-motor activities as well as cognitive abilities after taking the medication.

Top 5 AI Stocks to Buy for 2023

The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything. According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.

Click Here to Download the FREE Report.


Annovis observed improvements in many patients within a short treatment period. These promising results underscore Annovis Bio’s dedication to advancing buntanetap into an extended study. This future study aims to not only confirm the observed symptomatic improvements but also to investigate the drug’s potential disease-modifying properties.

Key Findings and Implications

Significant findings from the study include:

Cognitive Improvements

Buntanetap halted cognitive decline in all enrolled patients (MMSE 20-30) and enhanced cognition in those with mild dementia (MMSE 20-26). In the placebo group, cognition deteriorated throughout the study, whereas all treatment groups maintained their baseline levels, demonstrating a statistically significant effect of the drug in preventing cognitive decline.

Motor and Non-Motor Function

Buntanetap improved motor and non-motor PD-related functions in patients diagnosed for over three years. For patients with a diagnosis longer than three years, the 20mg dose of buntanetap significantly improved scores on the MDS-UPDRS Part II, Part III, Part II+III, and total scores compared to placebo and baseline.

Postural Instability and Gait Difficulty (PIGD)

The disease progresses faster in this group compared to other PD patients. Data indicated that PIGD patients responded better to buntanetap, showing greater improvement than other Parkinson’s patients.

Throughout the study, buntanetap maintained a consistent safety profile across all participants, with no significant differences observed between early and advanced PD patients, reinforcing previous Alzheimer’s disease (AD) data.

Most Popular

Related Posts